Financial reports 2026

Years First Quarter Second Quarter Third Quarter Fourth Quarter Interim Registration Document 2026         2025           URD  (fr)   2024           URD  (fr)   2023           URD  (fr)    Amendment(fr) 2022           URD  (fr) 2021  … Continue reading Financial reports 2026

Annual General Meeting

Annual General Meeting of May 22, 2026 2026 ORDINARY AND EXTRAORDINARY MEETING Location: TRANSGENE 400 boulevard Gonthier d’Andernach – Parc d’Innovation 67400 ILLKIRCH-GRAFFENSTADEN – FRANCE Date and Time: May 22, 2026 at 11 am CET Webcast link to French language conference call (live and deferred)   Documents Notice of 2026 Meeting Notice of the 2026… Continue reading Annual General Meeting

Analysts

Company Analyst E-mail Phone Kempen Chiara Montironi c.montironi@vanlanschotkempen.com + 31 610552719 Intron Health Naresh Chouhan naresh@intronhealthresearch.com +44 207 375 9143 Invest Securities Jamila El Bougrini jelbougrini@invest-securities.com +33 (0)1 44 88 88 09 Oddo BHF Martial Descoutures martial.descoutures@oddo-bhf.com +33 (0)1 44 51 85 00 Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by… Continue reading Analysts

General

Stock price Follow Transgene’s share price and all its stock market news live on Euronext General Stock Market Euronext Paris – Eurolist (compartiment B) Reuters / Bloomberg TRNG.PA / TNG.FP ISIN Code FR0005175080 Total number of shares outstanding 274,186,709 Initial Public Offering (IPO) March 26, 1998 Local Sector Index Next Biotech Financial Year Ends December… Continue reading General

Financial information

  Key figures arrow_downward Financial reports arrow_downward Regulated information arrow_downward

Key figures

In € million except share and per share data 2025 2024 2023 2022 2021 2020 2019 Revenue 7.2 6.4 7.9 10.3 17.4 9.9 13.7 R&D Expense -33.9 -34.3 -29.6 -32.2 -32.9 -27.3 -31.4 G&A Expense -7.3 -7.8 -7.0 -7.9 -7.4 -6.5 -7.1 Net income (loss) -37.5 -34 -22.3 -32.8 -19.5 -17.2 -18.8 Net Cash Burn… Continue reading Key figures

Regulated information

Transgene announces the success of its capital increase. Learn more about the details of the operation. The following pages contain information regarding the rights offering of Transgene. For regulatory reasons, the distribution of the content of this site is restricted. Consequently, please fill out the fields below to access the following pages. ➜ Learn More… Continue reading Regulated information